Edigene is a Beijing, China-based genome-editing CRO and potentially therapeutics company, spun out of Peking University’s School of Life Sciences. Edigene is one of only a handful of institutions around the world with proven track record, and publications in journals, in deploying CRISPR-CAS9 and in genome-editing technologies. Edigene’s first targeted milestone is to become the world’s first company to have a complete single gene ‘knockout’ library of the entire human genome, to better understand disease biology. And further strategic direction of Edigene is eventually to identify a promising therapeutic direction.

Learn more: http://edigene.com/